ENVISAGE and the Wistar Institute forge new venture and value creation partnership

March 10, 2015

PHILADELPHIA--(Mar. 10, 2015)--The Wistar Institute, an international leader in biomedical research, and ENVISAGE L.L.C, a prodigious life sciences venture creation and management firm, are pleased to announce a powerful partnership that leverages Wistar's innovative, high-impact science and ENVISAGE's expertise in managing immunology-infectious disease centered ventures.

"Our unique partnership emanates from pure synergy and collective desire to accelerate the advancement of Wistar's pipeline of value-added, early-stage assets beyond the typical academic technology transfer offering--we are taking active steps to further de-risk our portfolio while ensuring a higher likelihood of success for each and every one of our start-ups founded on Wistar Science," said Heather A. Steinman, Ph.D., M.B.A., The Wistar Institute Vice President for Business Development and Executive Director, Technology Transfer. "We know that our partners will only invest in start-ups with a strong management team in place, and ENVISAGE epitomizes that core capability--that glue. Together, we are the ideal model that can efficiently translate academic discoveries into value-added products that cater to the many unmet patient needs."

Partnering to build successful ventures is the ultimate goal of academia and industry partners alike. The traditional academic venture creation model revolves around identifying a university technology that could become a venture and then finding a management team to advance the venture forward. With this partnership, both ENVISAGE and Wistar aim to streamline this process by combining Wistar's ability to deliver cutting-edge, early-stage assets with ENVISAGE's management expertise (a relationship that is essential to driving early stage ventures towards an inflection point that exceeds both investor and partner expectations).

"We have established a team-driven relationship with Wistar whereby we are not just commercializing, we are becoming operationally involved with each venture," said Vik Subbu, Managing Partner of ENVISAGE L.L.C. "Immunology is our core area of interest and is a strategic fit with Wistar's strength and capabilities. When you combine this vision with Heather's entrepreneurial spirit, you've got a unique public-private model that bridges the translational gap between academic discovery and clinical development."

"As a leading NCI-designated cancer center, our scientific efforts are often focused on finding new solutions for treating cancer," said Dario C. Altieri, M.D., CEO of The Wistar Institute, Director of Wistar's Cancer Center, and the Robert and Penny Fox Distinguished Professor. "We are pleased to be teaming up with ENVISAGE in the immunology-infectious disease space, an important pillar of Wistar Science that we are expanding over the next several years."
ENVISAGE L.L.C works with a network of key opinion leaders, resident scientists, product development partners, and an experienced board of advisors to advance promising life-sciences innovations into value-add ventures. For more information, visit http://www.envisage-llcs.com.

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. Wistar Science Saves Lives. On the Web at http://www.wistar.org.

The Wistar Institute

Related Biomedical Research Articles from Brightsurf:

General data protection regulation hinders global biomedical research
The European Union (EU) General Data Protection Regulation (GDPR) was designed to give EU citizens greater protection and control of their personal data, particularly when transferred to entities outside the EU.

Novel educational program puts a human face on biomedical research
The goal of translational research is to speed research breakthroughs into clinical practice.

Biomedical research may miss key information by ignoring genetic ancestry
A new study of Black residents of four distinct US cities reveals variations in genetic ancestry and social status that underscore the inadequacy of using skin color as a proxy for race in research.

Advances in cryo-EM materials may aid cancer and biomedical research
Cryogenic-Electron Microscopy (cryo-EM) has been a game changer in the field of medical research, but the substrate, used to freeze and view samples under a microscope, has not advanced much in decades.

World-first program uncovers errors in biomedical research results
Just like the wrong ingredients can spoil a cake, so too can the wrong ingredients spoil the results in biomedical research.

Scientists poised to study reproducibility of Brazilian biomedical research
A project to assess the reproducibility of biomedical research in Brazil has been described today in the open-access journal eLife.

Transparency and reproducibility of biomedical research is improving
New research publishing Nov. 20 in the open-access journal PLOS Biology from Joshua Wallach, Kevin Boyack, and John Ioannidis suggests that progress has been made in key areas of research transparency and reproducibility.

As private funding of biomedical research soars, new risks arise
Academic medical centers (AMCs) in the US are navigating an increasing shift in research funding from historic public funding (e.g., NIH) to private sources such as pharma and biotech companies, foundations, and charities, raising a host of new issues related to collaborative research models, intellectual property rights, and scientific and ethical oversight.

BGRF scientists co-publish research paper on blockchain & AI for biomedical applications
Biogerontology Research Foundation Chief Science Officer (CSO) co-authored the landmark paper in the journal Oncotarget on the convergence of blockchain and AI to decentralize and galvanize healthcare and biomedical research.

Promising new drug for Hep B tested at Texas Biomedical Research Institute
Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

Read More: Biomedical Research News and Biomedical Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.